# A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers

> **NCT05911828** · PHASE1 · RECRUITING · sponsor: **Zydus Lifesciences Limited** · enrollment: 36 (estimated)

## Conditions studied

- Uncomplicated Malaria
- Asymptomatic Condition
- Falciparum Malaria

## Interventions

- **DRUG:** ZY19489 + Ferroquine (FQ)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05911828
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-05-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911828, "A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05911828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*